Search Results

With the approval of Wegovy HD, Novo Nordisk joins Johnson & Johnson, Boehringer Ingelheim and USAntibiotics as beneficiaries of the FDA’s Commissioner’s National Priority Voucher program, which aims to review products that align with certain national priorities in less than two months.

Partnership will enhance physician awareness of START’s portfolio of trials, streamline referrals, and support patient access to early-phase oncology research

● Findings from collaboration with global immunology company argenx show HypoSkin as translational human-based New Approach Methodology (NAM) platform ● SOT 2026 poster on early local tolerance screening demonstrates potential to reduce reliance on animal testing

CEO, Daniel Haders II, PhD, to address the inference throughput barrier in AI-driven drug discovery and lead a roundtable on deploying LLMs and AI agents to navigate the multi-parameter optimization challenge in small molecule drug design

Bio-IT World Conference & Expo is the world’s premier event showcasing technologies and analytic approaches that solve problems, accelerate science, and drive the future of precision medicine. Bio-IT World unites a global community of experts in life sciences, pharmaceuticals, clinical research, healthcare, informatics, and IT, all dedicated to advancing biomedical research, drug discovery and development, and healthcare innovations.

The company is establishing commercial production capabilities to fuel plans to launch autologous CAR-T cell therapies in China.

Sarepta Therapeutics says the FDA has agreed to review a regulatory package for Amondys 45 and Vyondys 53 after they failed a confirmatory trial, but whether the agency will agree to approve them is still unknown.